Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Current Leases (2019 - 2025)

Seres Therapeutics (MCRB) has disclosed Current Leases for 7 consecutive years, with $10.4 million as the latest value for Q4 2025.

  • Quarterly Current Leases rose 19.78% to $10.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.4 million through Dec 2025, up 19.78% year-over-year, with the annual reading at $10.4 million for FY2025, 19.78% up from the prior year.
  • Current Leases hit $10.4 million in Q4 2025 for Seres Therapeutics, up from $9.9 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $10.4 million in Q4 2025 to a low of $3.6 million in Q4 2022.
  • Historically, Current Leases has averaged $7.2 million across 5 years, with a median of $7.0 million in 2022.
  • Biggest five-year swings in Current Leases: crashed 45.52% in 2022 and later surged 84.64% in 2024.
  • Year by year, Current Leases stood at $6.6 million in 2021, then plummeted by 45.52% to $3.6 million in 2022, then soared by 55.15% to $5.6 million in 2023, then soared by 55.25% to $8.7 million in 2024, then increased by 19.78% to $10.4 million in 2025.
  • Business Quant data shows Current Leases for MCRB at $10.4 million in Q4 2025, $9.9 million in Q3 2025, and $9.5 million in Q2 2025.